Lipid Nanoparticles for miR-182-3p delivery in the treatment of triple negative breast cancer

Alessia Angelillo – PhD student, Department of Pharmacy, University of Naples Federico II; Annamaria Biroccio – Researcher, IRCCS Regina Elena National Cancer Institute, Rome; Virginia Campani – Associate Professor, Department of Life Sciences, Health and Health Professions, University of Rome Link Campus; Giuseppe De Rosa – Full Professor, Department of Pharmacy, University of Naples Federico II; Valeria Nele – RTDA, Department of Pharmacy, University of Naples Federico II; Manuela Porru – Researcher, IRCCS Regina Elena National Cancer Institute, Rome

Introduction:

Triple-negative breast cancer (TNBC) is the most aggressive subtype, lacking ER, PR and HER2, with few therapies and poor prognosis. Telomere Repeat-binding Factor 2 (TRF2), a core shelterin protein, promotes TNBC tumorigenesis through telomeric and extratelomeric functions and represents a promising therapeutic target (1). In this context, miR-182-3p was identified as a post-transcriptional regulator of TRF2 and lipid nanoparticle formulations were developed to enhance its delivery to TNBC cells, enabling a novel miRNA-based strategy potentially combinable with current therapies (2).